Tacrolimus (CAS 104987-11-3) /API

Tacrolimus (CAS 104987-11-3) is a high-purity pharmaceutical API classified as a potent calcineurin inhibitor, featuring a macrocyclic lactone molecular structure derived from Streptomyces tsukubaensis. It exerts targeted immunosuppressive effects by binding to FK-binding protein 12 (FKBP12), forming a complex that inhibits calcineurin—blocking T-cell activation and cytokine production. Unlike corticosteroids, it offers potent immunosuppression with lower systemic side effects, making it a gold standard for transplant rejection prevention.

It caters to the core needs of transplant medicine manufacturers, autoimmune therapy developers, and clinical supply chains. Widely applied in organ transplantation (kidney, liver, heart) and treating autoimmune diseases (atopic dermatitis, rheumatoid arthritis), it aligns with demand for precise, well-tolerated immunosuppressive therapies. Produced under strict GMP standards, each batch undergoes rigorous purity and stability testing to meet international pharmacopoeia requirements, ensuring consistency for clinical use. For businesses prioritizing life-saving immunosuppressive solutions, this Tacrolimus API serves as a critical raw material for advancing transplant and autoimmune medication development.is.